Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Current prostate-specific membrane-antigen (PSMA) targeted radioligand therapy (RLT) trials use conservative dose constraints, potentially limiting effectiveness.
• The optimal dose and regimen for PSMA-RLT in metastatic castration-resistant prostate cancer (mCRPC) remain undetermined.
• There is a need to evaluate whether intensified dosing strategies improve patient outcomes.

Purpose of the Study:

• To evaluate the scientific evidence and rationale for dose intensification in PSMA-RLT.
• To compare the safety and depth of response between an intense-induction then maintenance dosing regimen and standard-of-care dosing in the OPTIMAL-PSMA trial.
• To assess the impact of intensified [177Lu]Lu-PSMA-597 dosing on patients with mCRPC.

Main Methods:

• Review of existing scientific literature and clinical trials on PSMA-RLT dose-dense regimens.
• Overview of the OPTIMAL-PSMA trial design, comparing intense induction-maintenance dosing versus standard six doses 6-weekly [177Lu]Lu-PSMA-597.
• Analysis of safety and response depth in mCRPC patients.

Main Results:

• Existing trials are exploring various dose-dense regimens for PSMA-RLT.
• The OPTIMAL-PSMA trial is designed to provide comparative data on intense versus standard dosing.
• Evidence is emerging on the potential benefits and safety of dose escalation in PSMA-RLT.

Conclusions:

• Dose intensification in PSMA-RLT warrants further investigation to optimize patient outcomes.
• The OPTIMAL-PSMA trial is crucial for determining the safety and efficacy of intensified dosing strategies.
• Future research should focus on establishing safe and effective dose regimens for PSMA-RLT in mCRPC.